|Place of Origin:||China|
|Brand Name:||Senwayer Brand|
|Certification:||ISO, 9001, USP|
|Minimum Order Quantity:||10grams|
|Price:||Discount is possible if your order is big enough|
|Packaging Details:||10g, 20g, 50g , 100g, 500g. 1kg, 10kg|
|Delivery Time:||within 2 working days|
|Payment Terms:||T/T in advance, Money Gram, Western Union, Bank Transfer.|
pharmaceutical raw material,
medical raw material
99% high Purity Raw Material Drug , BMS -790052 Daclatasvir Powder
|Boiling Point:||1071.239 °C at 760 mmHg|
|Flash Point:||601.664 °C|
Daclatasvir (USAN, formerly BMS-790052, trade name Daklinza) is a drug for the treatment of hepatitis C (HCV).
Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin, as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.
There has been significant controversy over the price that Bristol-Myers Squibb has chosen to charge for the drug.
Daclatasvir (brand name Daklinza) is a new medication used to treat hepatitis C.
Daclatasvir is an antiviral medicine that prevents hepatitis C virus (HCV) from multiplying in your body.
|Uses 3||Daclatasvir is used to treat genotype 3 chronic hepatitis C in adults without cirrhosis. This medicine is given together with another drug called sofosbuvir.|
For others, daclatasvir can shorten treatment when added to pegylated interferon and ribavirin. Successful treatment reduces the risk of long-term complications of hepatitis C such as liver cancer or needing a liver transplant.
How effective is daclatasvir
Daclatasvir works better for some people than for others. Several factors predict how well someone will respond, including HCV genotype, extent of liver damage and previous treatment history. People with liver cirrhosis do not respond as well as those with mild or moderate liver fibrosis. Depending on which drugs daclatasvir is combined with, people who are new to treatment may have a better chance of being cured than those with little or no response to prior treatment.
However, factors that traditionally predict poor response to interferon-based therapy do not make as much difference with interferon-free treatment. These factors may be overcome by prolonging treatment or by adding another direct-acting antiviral or ribavirin.